FibroBiologics (FBLG) director receives grant of 30,803 stock options at $0.7503
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
FibroBiologics, Inc. director Robert E. Hoffman reported receiving a grant of stock options. He was awarded stock options covering 30,803 shares of common stock at an exercise price of $0.7503 per share, expiring on June 22, 2036. These options will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting. Following this compensation-related grant, Hoffman holds 30,803 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Hoffman Robert E.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 30,803 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 30,803 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 30,803 options
Exercise price: $0.7503 per share
Expiration date: June 22, 2036
+1 more
4 metrics
Option grant size
30,803 options
Stock Option (Right to Buy) grant to director
Exercise price
$0.7503 per share
Strike price for granted stock options
Expiration date
June 22, 2036
Option expiration for this grant
Total options after grant
30,803 options
Total derivative holdings following transaction
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vest in full, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 0.7503"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"The options will vest in full upon the earlier of (i) the first anniversary"
annual meeting financial
"or (ii) the date of the next annual meeting."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
What insider transaction did FibroBiologics (FBLG) report for Robert E. Hoffman?
FibroBiologics reported that director Robert E. Hoffman received a grant of stock options for 30,803 shares. The options are a compensation-related award, not an open-market purchase, and give him the right to buy common stock at a fixed exercise price.
How many FibroBiologics (FBLG) options did Robert E. Hoffman receive?
Robert E. Hoffman received stock options covering 30,803 shares of FibroBiologics common stock. After this grant, his reported derivative holdings consist of 30,803 stock options, reflecting the full amount awarded in this Form 4 filing.
What is the exercise price of Robert E. Hoffman’s FibroBiologics (FBLG) options?
The granted stock options have an exercise price of $0.7503 per share. This means Hoffman can buy FibroBiologics common stock at $0.7503 per share when the options are vested and exercisable, up until their stated expiration date.
When do Robert E. Hoffman’s FibroBiologics (FBLG) options vest?
The options will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting. This single-vesting schedule means all 30,803 options become exercisable at that earlier event.
What is the expiration date of Robert E. Hoffman’s FibroBiologics (FBLG) option grant?
The stock options granted to Robert E. Hoffman expire on June 22, 2036. He may exercise vested options any time before that expiration date, subject to the company’s equity plan and any applicable insider trading policies.
Is Robert E. Hoffman’s FibroBiologics (FBLG) option grant an open-market purchase?
No, the Form 4 describes a grant categorized as a “Grant, award, or other acquisition.” It is a compensation-related stock option award with a $0.7503 exercise price, not an open-market share purchase on a stock exchange.